Showing results (21-30 of 30) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Translational Oncology|March 8, 2016
PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with ChemotherapySteffen Filskov Sorensen, Wei Zhou, Marisa Dolled-Filhart, et al.Cancer Research and Treatment|March 18, 2017
Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with <i>EGFR</i>-Mutant Non-small Cell Lung CancerJong Ho Cho, Wei Zhou, Yoon-La Choi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 23, 2016
Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected CasesJong-Mu Sun, Wei Zhou, Yoon-La Choi, et al.International Journal of Radiation Oncology, Biology, Physics|November 28, 2012
RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patientsArnab Chakravarti, Meihua Wang, H Ian Robins, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2010
Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibitionAntonio Gualberto, Marisa Dolled-Filhart, Mark Gustavson, et al.Clinical Lung Cancer|July 4, 2017
Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor SamplesJong Ho Cho, Steffen Filskov Sorensen, Yoon-La Choi, et al.Lancet (London, England)|December 30, 2015
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialRoy S Herbst, Paul Baas, Dong-Wan Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion CohortLaura Q M Chow, Robert Haddad, Shilpa Gupta, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2016
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in MelanomaAdil I Daud, Jedd D Wolchok, Caroline Robert, et al.The New England Journal of Medicine|April 21, 2015
Pembrolizumab for the treatment of non-small-cell lung cancerEdward B Garon, Naiyer A Rizvi, Rina Hui, et al.Pageof 3